A positive interaction between inhibitors of protein synthesis and cefepime in the fight against methicillin-resistant Staphylococcus aureus

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 32, Issue 7, 2013, Pages 899-907

  Guignard, B ^a,b   Vouillamoz, J ^a   Giddey, M ^a   Moreillon, P ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOSERINE; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; FOSFOMYCIN; FUSIDIC ACID; LINEZOLID; TEICOPLANIN; TETRACYCLINE; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; CONTROLLED STUDY; DRUG POTENTIATION; FEM GENE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MUTANT; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; DRUG SYNERGISM; MICROBIAL SENSITIVITY TESTS; PROTEIN SYNTHESIS INHIBITORS; STAPHYLOCOCCUS AUREUS;

EID: 84879138311     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-013-1824-x     Document Type: Article

References (36)

1. Guignard B, Entenza JM, Moreillon P (2005) Beta-lactams against methicillin-resistant Staphylococcus aureus. Curr Opin Pharmacol 5(5):479-489
2. Wertheim HF, Melles DC, Vos MC, van Leeuwen W, van Belkum A, Verbrugh HA, Nouwen JL (2005) The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis 5(12):751-762
3. Kuroda M, Ohta T, Uchiyama I, Baba T, Yuzawa H, Kobayashi I, Cui L, Oguchi A, Aoki K, Nagai Y, Lian J, Ito T, Kanamori M, Matsumaru H, Maruyama A, Murakami H, Hosoyama A, Mizutani-Ui Y, Takahashi NK, Sawano T, Inoue R, Kaito C, Sekimizu K, Hirakawa H, Kuhara S, Goto S, Yabuzaki J, Kanehisa M, Yamashita A, Oshima K, Furuya K, Yoshino C, Shiba T, Hattori M, Ogasawara N, Hayashi H, Hiramatsu K (2001) Whole genome sequencing of meticillin-resistant Staphylococcus aureus. Lancet 357(9264):1225-1240
4. Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML (2010) Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 23(1):99-139
5. Sorlozano A, Gutierrez J, Martinez T, Yuste ME, Perez-Lopez JA, Vindel A, Guillen J, Boquete T (2010) Detection of new mutations conferring resistance to linezolid in glycopeptide-intermediate susceptibility Staphylococcus hominis subspecies hominis circulating in an intensive care unit. Eur J Clin Microbiol Infect Dis 29(1):73-80
6. Shakil S, Akram M, Khan AU (2008) Tigecycline: a critical update. J Chemother 20(4):411-419
7. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J (2009) Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48(1):1-12
8. Lim D, Strynadka NC (2002) Structural basis for the beta lactam resistance of PBP2a from methicillin-resistant Staphylococcus aureus. Nat Struct Biol 9(11):870-876
9. Moreillon P (2008) New and emerging treatment of Staphylococcus aureus infections in the hospital setting. Clin Microbiol Infect 14(SUPPL 3):32-41
10. Llarrull LI, Fisher JF, Mobashery S (2009) Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new beta-lactams that meet the challenge. Antimicrob Agents Chemother 53(10):4051-4063
11. Climo MW, Ehlert K, Archer GL (2001) Mechanism and suppression of lysostaphin resistance in oxacillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 45(5):1431-1437
12. Vouillamoz J, Entenza JM, Féger C, Glauser MP, Moreillon P (2000) Quinupristin-dalfopristin combined with beta-lactams for treatment of experimental endocarditis due to Staphylococcus aureus constitutively resistant to macrolide-lincosamide-streptogramin B antibiotics. Antimicrob Agents Chemother 44(7):1789-1795
13. Sieradzki K, Tomasz A (1997) Suppression of beta-lactam antibiotic resistance in a methicillin-resistant Staphylococcus aureus through synergic action of early cell wall inhibitors and some other antibiotics. J Antimicrob Chemother 39(SUPPL A):47-51
14. Allen GP, Cha R, Rybak MJ (2002) In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 46(8):2606-2612
15. Vaudaux PE, Monzillo V, Francois P, Lew DP, Foster TJ, Berger-Bächi B (1998) Introduction of the mec element (methicillin resistance) into Staphylococcus aureus alters in vitro functional activities of fibrinogen and fibronectin adhesins. Antimicrob Agents Chemother 42(3):564-570
16. Blanc DS, Petignat C, Moreillon P, Entenza JM, Eisenring M, Kleiber H, Wenger A, Troillet N, Blanc C, Francioli P (1999) Unusual spread of a penicillin-susceptible methicillin-resistant Staphylococcus aureus clone in a geographic area of low incidence. Clin Infect Dis 29(6):1512-1518
17. Murakami K, Tomasz A (1989) Involvement of multiple genetic determinants in high-level methicillin resistance in Staphylococcus aureus. J Bacteriol 171(2):874-879
18. Franciolli M, Bille J, Glauser MP, Moreillon P (1991) Beta-lactam resistance mechanisms of methicillin-resistant Staphylococcus aureus. J Infect Dis 163(3):514-523
19. Beck WD, Berger-Bächi B, Kayser FH (1986) Additional DNA in methicillin-resistant Staphylococcus aureus and molecular cloning of mec-specific DNA. J Bacteriol 165(2):373-378
20. Henze U, Sidow T, Wecke J, Labischinski H, Berger-Bächi B (1993) Influence of femB on methicillin resistance and peptidoglycan metabolism in Staphylococcus aureus. J Bacteriol 175(6):1612-1620
21. Strandén AM, Ehlert K, Labischinski H, Berger-Bächi B (1997) Cell wall monoglycine cross-bridges and methicillin hypersusceptibility in a femAB null mutant of methicillin-resistant Staphylococcus aureus. J Bacteriol 179(1):9-16
22. Amsterdam D (1996) Susceptibility testing of antimicrobials in liquid media. In: Lorian V (ed) Antibiotics in laboratory medicine. The Williams & Wilkins Co., Baltimore, pp 52-111
23. Eliopoulos GM, Moellering RC Jr (1996) Antimicrobial combinations. In: Lorian V (ed) Antibiotics in laboratory medicine. The Williams & Wilkins Co., Baltimore, pp 330-396
24. Que YA, Entenza JM, Francioli P, Moreillon P (1998) The impact of penicillinase on cefamandole treatment and prophylaxis of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. J Infect Dis 177(1):146-154
25. Utsui Y, Ohya S, Magaribuchi T, Tajima M, Yokota T (1986) Antibacterial activity of cefmetazole alone and in combination with fosfomycin against methicillin- and cephem-resistant Staphylococcus aureus. Antimicrob Agents Chemother 30(6):917-922
26. de Jonge BL, Tomasz A (1993) Abnormal peptidoglycan produced in a methicillin-resistant strain of Staphylococcus aureus grown in the presence of methicillin: functional role for penicillin-binding protein 2A in cell wall synthesis. Antimicrob Agents Chemother 37(2):342-346
27. Berger-Bächi B, Rohrer S (2002) Factors influencing methicillin resistance in staphylococci. Arch Microbiol 178(3):165-171
28. de Lencastre H, de Jonge BL, Matthews PR, Tomasz A (1994) Molecular aspects of methicillin resistance in Staphylococcus aureus. J Antimicrob Chemother 33(1):7-24
29. Rohrer S, Berger-Bächi B (2003) FemABX peptidyl transferases: a link between branched-chain cell wall peptide formation and beta-lactam resistance in gram-positive cocci. Antimicrob Agents Chemother 47(3):837-846
30. Pachón-Ibáñez ME, Ribes S, Domínguez MA, Fernández R, Tubau F, Ariza J, Gudiol F, Cabellos C (2011) Efficacy of fosfomycin and its combination with linezolid, vancomycin and imipenem in an experimental peritonitis model caused by a Staphylococcus aureus strain with reduced susceptibility to vancomycin. Eur J Clin Microbiol Infect Dis 30(1):89-95
31. Pinho MG, Filipe SR, de Lencastre H, Tomasz A (2001) Complementation of the essential peptidoglycan transpeptidase function of penicillin-binding protein 2 (PBP2) by the drug resistance protein PBP2A in Staphylococcus aureus. J Bacteriol 183(22):6525-6531
32. Kusser W, Ishiguro EE (1986) Lysis of nongrowing Escherichia coli by combinations of beta-lactam antibiotics and inhibitors of ribosome function. Antimicrob Agents Chemother 29(3):451-455
33. Cassels R, Oliva B, Knowles D (1995) Occurrence of the regulatory nucleotides ppGpp and pppGpp following induction of the stringent response in staphylococci. J Bacteriol 177(17):5161-5165
34. Lorian V, Amaral L, Fernandes F (1995) RP 59500 postantibiotic effect defined by bacterial ultrastructure. Drugs Exp Clin Res 21(3):125-128
35. Utaida S, Dunman PM, Macapagal D, Murphy E, Projan SJ, Singh VK, Jayaswal RK, Wilkinson BJ (2003) Genome-wide transcriptional profiling of the response of Staphylococcus aureus to cell-wall-active antibiotics reveals a cell-wall-stress stimulon. Microbiology 149(Pt 10):2719-2732
36. Jordan S, Hutchings MI, Mascher T (2008) Cell envelope stress response in Gram-positive bacteria. FEMS Microbiol Rev 32(1):107-146